From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 06 Nov 2019
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
News / 04 Nov 2019
Summit Therapeutics Recognises C. difficile Awareness Month
News / 16 Oct 2019
Summit Therapeutics to Present at the 2019 BIO Investor Forum
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
Ridinilazole for CDI
Find out more about our precision antibiotic ridinilazole for the treatment of CDI
R&D Day
A webcast replay is available of the event held in New York on 7 October 2019
Our Discuva Platform
Our technology platform is at the heart of our research to develop new mechanism antibiotics